KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Receivables - Other: 2017-2024

Historic Receivables - Other for Aquestive Therapeutics (AQST) over the last 8 years, with Dec 2024 value amounting to $2.5 million.

  • Aquestive Therapeutics' Receivables - Other rose 16.37% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year increase of 16.37%. This contributed to the annual value of $2.5 million for FY2024, which is 15.16% down from last year.
  • Latest data reveals that Aquestive Therapeutics reported Receivables - Other of $2.5 million as of FY2024, which was down 15.16% from $2.9 million recorded in FY2023.
  • Over the past 5 years, Aquestive Therapeutics' Receivables - Other peaked at $7.0 million during FY2020, and registered a low of $2.1 million during FY2022.
  • Moreover, its 3-year median value for Receivables - Other was $2.5 million (2024), whereas its average is $2.5 million.
  • As far as peak fluctuations go, Aquestive Therapeutics' Receivables - Other soared by 60.44% in 2020, and later slumped by 64.35% in 2022.
  • Over the past 5 years, Aquestive Therapeutics' Receivables - Other (Yearly) stood at $7.0 million in 2020, then decreased by 14.29% to $6.0 million in 2021, then tumbled by 64.35% to $2.1 million in 2022, then skyrocketed by 36.28% to $2.9 million in 2023, then declined by 15.16% to $2.5 million in 2024.